Obesity-drug leader Eli Lilly (LLY) is within striking distance of a new buy point following a strong quarterly earnings report. That makes Eli Lilly stock Wednesday's pick for IBD 50 Growth Stocks To Watch from Investor's Business Daily. The company develops and sells medicines across diabetes, obesity, immunology, oncology and neuroscience markets.
Eli Lilly stock boasts an ideal score of…
Extract — continue reading at the source.
Related stories
Microsoft Earns 31% More Than It Did a Year Ago and Is Worth Less
Xpeng posts huge funding round for robotics unit
U.S. Treasury Secretary Scott Bessent's Plan to Calm the Bond Market Could Have Unintended Consequences for Fed Chair Kevin Warsh
The ugly math on interest expenses, yields and the $40 trillion U.S. national debt
Stanley Druckenmiller takes aim at former colleague Scott Bessent
Dimension Energy Secures $857 Million to Support Distributed Solar